Skip to main content

Table 6 Magnitude of effects of SMT and GE intervention on primary and secondary outcomes

From: Effects of a movement control and tactile acuity training in patients with nonspecific chronic low back pain and control impairment – a randomised controlled pilot study

 

Median (IQR) t1a

Median (IQR) t1b

Median (IQR) t2

t1a vs. t1b (ICC)

Intragroup comparison t1a vs t2 p (r)

Intragroup Δt2-t1a median

Intergroup comparison of intragroup Δt2-t1a (p)

BPI Intensity

 SMT

3.50 (1.75–4.13)

3.00 (1.25–5.13)

1.13 (0.50–3.44)

0.85

0.01* (0.63)

-1.25

0.26

 GE

3.00 (2.19–4.19)

3.75 (1.50–3.94)

2.00 (1.81–3.00)

0.07

-0.88

BPI Interference

 SMT

1.93 (0.64–3.46)

1.57 (0.39–4.11)

0.36 (0.11–2.21)

0.90

≤0.001* (0.83)

-0.86

0.25

 GE

1.50 (0.89–2.82)

1.43 (0.64–2.39)

0.93 (0.29–2.61)

0.17

-0.50

RMDQ

 SMT

4.50 (2.00–8.75)

6.50 (2.75–10.25)

3.50 (1.00–7.00)

0.89

0.803

0.00

0.64

 GE

5.00 (1.50–6.00)

4.00 (2.00–5.00)

3.00 (2.00–4.75)

0.03* (0.53)

-1.00

ODI

 SMT

22.00 (9.50–30.50)

22.00 (13.50–32.00)

11.00 (6.00–26.50)

0.92

0.03* (0.51)

-3.00

0.97

 GE

20.00 (12.00–26.67)

17.89 (10.50–22.00)

16.00 (10.50–21.67)

0.03* (0.53)

-4.00

SF-36 PC

 SMT

38.62 (32.34–47.65)

38.98 (31.56–48.11)

46.43 (39.83–52.29)

0.91

0.01* (−0.67)

+6.47

0.11

 GE

45.47 (37.18–48.20)

45.64 (37.40–52.98)

47.83 (43.70–52.41)

0.15

+3.09

SF-36 MC

 SMT

50.51 (45.07–56.34)

53.51 (37.39–57.11)

55.40 (36.24–59.46)

0.94

0.94

+1.02

0.88

 GE

54.09 (44.11–58.72)

54.20 (47.70–59.23)

52.77 (48.62–58.52)

0.27

+0.66

2PD [mm]

 SMT

64.38 (48.75–76.88)

50.63 (46.88–63.75)

43.13 (35.00–66.56)

0.73

0.002* (0.75)

-13.13

0.09

 GE

60.63 (41.88–68.44)

58.75 (43.75–68.13)

53.13 (39.38–66.56)

0.20

-3.13

MCT [number of positive tests]

 SMT

4.00 (3.00–4.25)

4.00 (3.75–4.00)

1.50 (1.00–3.00)

0.85

≤0.001* (0.86)

-2.00

0.05*

 GE

4.00 (3.00–5.00)

4.00 (3.25–5.00)

3.50 (2.00–4.75)

0.05

-1.00

HADS A

 SMT

6.50 (3.00–10.25)

6.00 (2.75–11.00)

4.50 (2.75–9.25)

0.98

0.04* (0.50)

-1.00

0.67

 GE

5.50 (2.00–8.75)

4.50 (2.00–8.00)

4.50 (2.00–8.00)

0.10

-1.00

HADS D

 SMT

4.00 (1.00–6.00)

3.00 (1.00–5.25)

2.00 (1.00–5.00)

0.97

0.04* (0.50)

0.00

1.00

 GE

2.50 (1.00–4.50)

2.00 (1.00–4.75)

1.00 (0.25–5.75)

0.09

-1.00

 

FABQ Activity

 SMT

12.00 (10.75–15.25)

11.50 (8.75–14.50)

10.50 (6.75–12.00)

0.72

0.02* (0.53)

-1.50

0.44

 GE

9.50 (6.25–14.50)

10.50 (5.75–16.00)

10.00 (5.50–14.75)

0.68

-1.50

FABQ Work

 SMT

10.50 (2.00–18.00)

12.50 (3.75–21.25)

9.00 (2.75–19.00)

0.87

0.50

0.00

0.07

 GE

8.50 (2.00–19.25)

10.00 (1.25–15.75)

8.50 (1.25–12.00)

0.02* (0.57)

-2.00

  1. A Anxiety, BPI Brief Pain Inventory, D Depression, FABQ Fear Avoidance and Beliefs Questionnaire, GE General exercise programme, HADS Hospital Anxiety and Depression Scale, ICC Intraclass-correlation coefficient, MC Mental component, MCT Movement control tests, ODI Oswestry Disability Index, PC Physical component, RMDQ Roland Morris Disability Questionnaire, SF-36 Short-Form 36, SMT Specific sensorimotor treatment, t1a first measurement point, t1b second measurement point, t2 follow-up measurement, 2PD two-point discrimination
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us